Abstract: The present invention provides methods of modulating an immune response in an organism by administering medicinally active extracts and fractions, and a method for preparing the same by extracting and fractioning constituents from the tissue of components of Ganoderma lucidum.

Abstract: Phytoceutical composition for the prevention and treatment of inmune disorders. A specific combination of extracts of plants is taught, as well as the formulations based on categorizing plants into one of three groups, Energy, Bio-Intelligence and Organization.

Abstract: Basidiomycetes which is a novel mushroom having an excellent immunopotentiating action, etc., a Basidiomycetes extract composition, and health foods and immunopotentiators using the Basidiomycetes extract composition are provided. Basidiomycetes has no basidium forming potential. In particular, Basidiomycetes is Basidiomycetes-X FERM BP-10011. A Basidiomycetes extract composition is extracted from them with an extraction solvent including at least one solvent selected from water and a hydrophilic solvent.

Abstract: Compounds having unique antiviral and antibacterial properties are prepared from medicinal mushroom mycelium, extracts and derivatives. The compositions are derived from Fomitopsis, Piptoporus, Ganoderma, Inonotus, Trametes, Pleurotus, and blends of medicinal mushroom species and are useful in preventing and treating viruses including Poxyiridae and Orthopox viruses, flu viruses including bird flu (H5N1), SARS and Hepatitis C(HCV), as well as infections from Mycobacterium tuberculosis, Staphylococcus aureus and Escherichia coli.

Abstract: Methods and compositions for reducing the levels of Advanced Glycation Endproducts (AGE) related proteins in the skin by topical application of dermatocosmetic compositions comprising effective amounts of extracts of Ganoderma lucidum that have been hydrolyzed by an acid protease, preferably Rhizomucor miehei, and thereafter rendered substantially devoid of acid-protease activity.

Abstract: The present invention relates to methods and compositions for reducing the appearance of dynamic facial wrinkles by administering oral and/or topical compositions comprising therapeutically-effective amounts of extracts of one or more relaxing herbal agents (“RHAs”) alone or in combination with one or more extracts of an edible solanaceous glycoalkaloid-containing plant (“ESGP”) or an edible glycoalkaloid-containing fungus (“EGF”) selected from plant species in the genus Solanum and mushrooms. RHAs are selected from the group consisting of extracts of Q. amara, E. angustifolia, P. oleracea, M. dubia, P. orientalis and A. muscaria and plant species from the genus Valeriana, Passiflora, Verbascum, Scutellaria, Cypripedium, Magnolia, Atriplex and Symphytum. Additionally, the methods of the present invention may comprise exfoliating the skin, preferably with at least one acid protease enzyme.

Abstract: The present invention relates to compositions comprising polypeptides and polysaccharides. The compositions are in general immune modulating. The invention also discloses methods of producing these compositions using filamentous fungi cultivated in liquid medium. The compositions are useful for example in the treatment of immune compromised conditions.

Abstract: The present invention provides an antioxidant and a whitening agent having high safety, and a external preparation for skin using the same. The antioxidant and whitening agent comprise, as an effective component, one or more extracts from Basidiomycetes selected from the group consisting of Pleurotus abalonus, Pholiota squarrosa, Onnia orientalis, Astraeus hygrometricus and Pleurotus nebrodensis. These extracts have a free radical capturing ability and are useful for suppressing skin oxidation and for preventing and improving skin aging. In addition, the extracts have a tyrosinase activity inhibiting action and can suppress the melanin generation. Since the fruit bodies of these Basidiomycetes have been used for edible purpose and have high safety, they can be used preferably for an external preparation for skin.

Abstract: Microsclerotia of entomopathogenic fungi, including Metarhizium species, Beauveria species, and Lecanicillium species, may be produced. These microsclerotia are effective for the control of a wide variety of insect pests, particularly soil-dwelling insect pests.

Abstract: A method for treating psoriasis by providing a pharmaceutical composition containing at least Ganoderma lucidum extract and administering a therapeutically effective amount of the composition to a patient in need thereof. Also disclosed is a method for treating psoriasis by first purifying Ganoderma lucidum extract into at least one fraction, then providing a pharmaceutical composition comprising at least one of the Ganoderma lucidum fractions, and administering a therapeutically effective amount of the composition to a patient in need thereof. A method for alleviating symptoms of psoriasis is disclosed. The symptoms of psoriasis are alleviated by providing a pharmaceutical composition containing at least Ganoderma lucidum extract and administering an amount of the composition effective to increase at least one of an IL-10 and IL-1Ra expression, whereby the symptoms of psoriasis are ameliorated.

Abstract: A method for treating an allergy by providing a pharmaceutical composition containing at least Ganoderma lucidum extract and administering a therapeutically effective amount of the composition to a patient in need thereof. Also disclosed is a method for treating an allergy by first purifying Ganoderma lucidum extract into at least one fraction, then providing a pharmaceutical composition comprising at least one of the Ganoderma lucidum fractions, and administering a therapeutically effective amount of the composition to a patient in need thereof. A method for alleviating symptoms of an allergy is disclosed. The symptoms of the allergy are alleviated by providing a pharmaceutical composition containing at least Ganoderma lucidum extract and administering an amount of the composition effective to decrease at least one of an IgE and IgG2a level, whereby the symptoms of the allergy are ameliorated.

Abstract: A Phytoceutical composition for the prevention and treatment of renal disorders is provided. A specific combination of extracts of plants is taught, as well as principles for varying the formulations based on categorizing plants into one of three groups, Energy, Bio-Intelligence, and Organization and selecting several plants from each group. Such combinations have effects, with minimal side effects.

Abstract: The inhibitor of Hepatitis B virus and HIV activity according to the present invention comprises a Lentinus edodes mycelium extract obtained by the steps of inoculating Lentinus edodes fungus in a solid culture medium comprising bagasse, then disentangling the solid culture medium containing the proliferated mycelium, adding water and at least one enzyme selected from a group consisting of cellulase, protease and glucosidase to the disentangled solid culture medium with keeping the solid culture medium at 30 to 50° C., grinding and milling the solid culture medium in the presence of the enzyme to obtain a Lentinus edodes mycelium extract, and then heating the extract to a temperature of not higher than 95° C. to inactivate the enzyme and sterilize the extract.

Abstract: The present invention utilizes extracts of the pre-sporulation (preconidial) mycelial stage of entomopathogenic fungi as insect attractants and/or pathogens. The fungus can be cultivated on grain, wood, agricultural wastes or other cellulosic material. More than one fungus and substrate can be used in combination.

Abstract: Provided are methods of treating patients suffering from or susceptible to at least one symptom of abuse of, dependence on, or withdrawal from at least one substance with Compound A. Also provided are methods of treating at least one phase of substance dependence on at least one substance in patients and certain methods of treating at least one phase of cocaine dependence in patients.

Abstract: A physiologically active substance NK13650P3 having the following physicochemical properties or a pharmacologically acceptable salt thereof. 1) Appearance: pale yellow powder 2) Molecular formula: C29H37N7O15 3) Molecular weight: 723 4) Hydrogen nuclear magnetic resonance spectrum: spectrum measured at 600 MHz in heavy water contains the following signals: chemical shift value ? ppm: 7.05(1H, 3), 7.00(1H, d), 6.96(1H, d), 6.83(1H, s), etc. 5) Carbon nuclear magnetic resonance spectrum: spectrum measured at 150 MHz in heavy water contains the following signals: chemical shift value ? ppm: 181.5(s), 181.4(s), 179.9(s), 179.2(s), 174.5(s), 174.3(s), 171.5(s), 165.4(s), etc. 6) Ultraviolet light spectrum: spectrum measured in aqueous solution contains the following UV absorption bands: ?max (MeOH): 196.5 nm, 224.5 nm, 322.5 nm 7) Solubility: highly soluble in water but insoluble in methanol, acetone, ethyl acetate, chloroform and dimethyl sulfoxide.

Abstract: A dietary supplement composition comprising a therapeutically effective amount of at least one sirt 1 activating agent, a therapeutically effective amount of at least one Qi activating agent, and a therapeutically effective amount of at least one adaptogen is disclosed. An optional herbal treatment for stress-related deep wrinkles comprises chronic oral administration for at least two weeks of a beverage containing an effective amount of a valerian root extract sufficient to provide a desired reduction in the appearance of the deep wrinkles. A photoprotective agent may also be included. Also included are a microcirculation increasing agent. Also optional are an herbal toner and topical cellulite product.

Abstract: Dietary supplements and methods for management and control of body weight comprising at least one liver protecting agent and at least one mushroom in the form of powder, extract, or combinations thereof.

Abstract: Disclosed are methods of producing modified microcrystalline chitosan. Chitosan in aqueous solution is degraded enzymatically, hydrolytically or oxidatively. The chitosan solution is then alkalized with agitation using aqueous hydroxides and/or their salts to attain a pH not lower than 7.0. The precipitated modified microcrystalline chitosan is highly pure and may be concentrated and dried according to known methods. Methods according to the invention also include methods by which an aqueous solution of chitosan is first alkalized using hydroxides and/or their salts to a pH not lower than 7.0. Then the precipitated microcrystalline chitosan is subjected to enzymatic or oxidative degradation to achieve a desired average molecular weight and polydispersity. The product is highly pure and may be concentrated and dried according to known methods.

Abstract: The present invention provides a method for treating photoreceptor cell degeneration in a mammal. The method includes orally administering a composition comprising germination activated sporoderm-broken Ganoderma lucidum spore oil (“GLS oil”) or a mixture of GLS oil and docosahexaenoic acid (DHA), to a mammal suffering from photoreceptor cell degeneration.

Abstract: Cosmetic or dermopharmaceutical compositions which contain kombucha are disclosed. The present invention further relates to the use of kombucha and cosmetic or dermopharmaceutical compositions containing the same, alone or in combination, for the care of the skin, mucosae and skin appendages, and in particular for preventing the signs of endogenous and/or exogenous ageing.

Abstract: A novel substance that has the physiological activity of the aglycone of isoflavones and the physiological activity of the culture of the basidiomycetes with the physiological activities being synergistically enhanced, obtained by cultivating a basidiomycetes having a ?-glucosidase activity in a medium containing an isoflavone, a method for producing it, and food, feedstuff and medicine containing it. The substance of the invention is improved in the physiological effect of the aglycone of isoflavones and the physiological effect of the culture of the basidiomycetes, and is not only useful as an anti-tumor agent but also is useful for therapy and/or prevention of osteoporosis and also as an immune enhancement agent.

Abstract: The invention provides means and methods for determining whether a sample is derived from an individual suffering from inflammatory arthritis or from an individual at risk of suffering there from, said method comprising measuring in said sample the level of expression of at least one gene product of a gene of table A, table B or and comparing said expression level with a reference value. Further provided is a non-human animal model comprising an altered expression of a gene of table A, table B or when compared to a reference non-human animal, and use of this model as or in an arthritis model. Further provided is an in vitro assay for screening compounds for effect on a phenotype of synovial fibroblasts. The synovial fibroblast are preferably derived from a human or non-human animal suffering from inflammatory arthritis.

Abstract: The invention relates to uses and methods relating to grass and endophyte combinations to repel avian species from the grass and endophyte combination. In particular, methods are described to select grass and endophyte combinations in order to enhance or maximise the repellent effect. Preferred endophyte and grass combinations are described which are based on the selection methods and include AR4, AR5, AR8 and AR94 (Deposit Nos. V07/029054, V07/029055, V071029056, V07/029057) in Lolium cultivars as well as AR601, AR602, AR603, and AR604 (Deposit Nos. V07/029058, V07/029059, V07/029060, V07/029061) in Festuca cultivars.

Abstract: The present invention generally relates to the use of a formula that improves human and animal endurance, stamina, performance and other physical parameters. In one composition aspect, the formula or composition of the present invention includes a Flammulina velutipes extract and citrus peel.

Abstract: A drug delivery device for placement in the eye includes a drug core comprising a hydrophobic pharmaceutically active agent, and a holder that holds the drug core. The holder is made of a material impermeable to passage of the active agent and includes an opening for passage of the pharmaceutically agent therethrough to eye tissue. The device includes polyurethane-siloxane-containing copolymers crosslinked with hydrophilic monomers.

Abstract: The present invention relates to novel active compound combinations comprising, firstly, known carboxamides and, secondly, insecticidally active compounds, which active compound combinations are highly suitable for controlling unwanted animal pests, such as insects or acarids, and also unwanted phytopathogenic fungi.

Abstract: Disclosed are topical compositions comprising extracts of Hypsizygus ulmarius in amounts that are effective to influence LTB4-mediated chemotaxis and/or IL-1? mediated adhesion of polymorphonuclear leukocytes. The hypsizygus ulmarius extract may be used alone or in combination with secondary anti-inflammatory and skin active agents, such as other mushroom and/or natural extracts. The secondary anti-inflammatory agents may or may not function by antagonizing LTB4-mediated chemotaxis and IL-1? mediated adhesion. The extract may be incorporated into a cosmetically acceptable vehicle. The present invention includes methods of treating skin inflammation by applying to inflamed skin, anti-inflammatory effective amounts of Hypsizygus ulmarius extract in a defined treatment regimen.

Abstract: A Phytoceutical composition for the prevention and treatment of hyperlipidemia—cholesterol and triglyceride disorder—is provided. A specific combination of extracts of plants and nutraceuticals is taught, as well as principles for varying the formulations based on categorizing plants and nutraceuticals into one of three groups, Energy, Bio-Intelligence, and Organization and selecting several plants and nutraceuticals from each group. Such combinations have synergistic effects, with minimal side effects.

Abstract: A composition comprising at least a therapeutically effective amount of L-carnitine fumarate, and an extract of Coleus forskohlii is provided to maintain androgen and androgen-like uptake potential in cells, via simultaneous increase in the availability of androgen receptors and improved availability of androgen and androgen-like molecules. A method of same is also provided. The present invention further comprises therapeutically effective amounts of one or more of N-acetyl L-carnitine, melatonin. ubidecarenone (coenzyme Q10), idebenone, decylubiquinone, an extract of Agaricus blazei Murill, and ginsenoside Rb1.

Abstract: The present invention provides methods of modulating an immune response in an organism by administering medicinally active extracts and fractions, and a method for preparing the same by extracting and fractioning constituents from the tissue of components of Ganoderma lucidum.

Abstract: A food material capable of suppressing the genesis of breast cancer or proliferation of terminal breast cancer. An extract of Agaricus Blazei Murill comprising an ingredient capable of suppressing the genesis of breast cancer or proliferation of terminal breast cancer is provided. This ingredient can be a chromatographic main elution fraction of 100 to 2000 molecular weight obtained through the steps of extracting the fruit body of Agaricus Blazei Murill with hot water, dialyzing the obtained extract and subjecting the obtained dialysis external fluid to chromatography. Alternatively, the above ingredient can be a dialysis external fluid obtained through the steps of extracting the fruit body of Agaricus Blazei Murill with hot water, adding ethanol to the obtained extract to thereby obtain precipitates, and dissolving the precipitates in water and dialyzing the resultant solution.

Abstract: A composition and methods of production are described including fungal material, a solid substrate and a biopolymer composition. The composition is described as being stable when stored for at least 7 months and also reduces dust losses normally attributed to fungal compositions. Uses are described for the composition including pest and weed treatments.

Abstract: The present invention relates to a paecilomyces genus microorganism and microbial insecticide for controlling the soil pests using the same, more particularly to a paecilomyces genus microorganism having insecticidal activity to soil pests and a microbial insecticide for controlling the soil pests containing the same. Since the microbial insecticide of the present invention shows excellent insecticidal activity to harmful soil pests, it can effectively be used as a environment-compatible insecticide to prevent the soil pests from farmland crops.

Abstract: The present disclosure provides medicinally active extracts and fractions, and methods for using the same to increase eukaryotic cell adhesion, to increase differentiation of eukaryotic cells to produce increased numbers of B cells dendritic cells and chodrocytes, and to maintain undifferentiated hematopoietic cells. These methods and useful for modulating immune response, modulating hematopoietic activity, and engineering certain types of eukaryotic tissues.

Abstract: The present invention provides a plant disease control agent which is stable and safe in terms of leaving no residue and a method for controlling plant diseases using the same. The plant disease control agent comprises a fragment of an inky cap mushroom, and plant diseases are controlled by using the plant disease control agent. The plant disease control agent may be a suspension comprising the fragment of the inky cap mushroom or a solid material composed of the suspension and a carrier to which the suspension is absorbed. The inky cap mushroom is preferably Coprinus curtus or the like, especially preferably Coprinus curtus GM-21 (NITE BP-37).

Abstract: The extraction of a microbial or single cell oil, for example comprising one or more polyunsaturated fatty acids (PUFAs), directly from microbial cells is disclosed which avoids the need for solvents. After fermentation, the microbial cells are pasteurised, washed and the cell walls lysed or disrupted by a mechanical (e.g. homogenisation), physical (boiling or drying), chemical (solvents) or enzymatic (cell wall degrading enzymes) technique. The oil (containing the PUFA) is then separated from the resulting cell wall debris. This is achieved by centrifugation, which results in an oily phase (top layer) that contains the oil which that can be separated from an aqueous phase (containing the cell wall debris). The oil can then be extracted and if necessary the PUFA can be purified or isolated from the oil.

Abstract: The present invention concerns the use of the mushroom Agaricus blazei Murill for producing a medication for combating or preventing bacterial and non-bacterial infections (e.g. parasites or virus) in a mammal as well as combating or preventing allergy in mammals. Such an infection may e.g. be caused by pneumococci and even more specifically where the mammal is a human.

Abstract: Pharmaceutical compositions of Usnea barbata and the use thereof for the treatment of skin diseases are disclosed. A preferred composition is the combination with an extract of Hypericum perforatum. The extracts are obtained by supercritical high-pressure extraction with spring carbon-dioxide. A preferred form of preparation is the homogenization of 6% by weight of an extract of Usnea barbata, containing 96% of usnic acid, and 40% by weight of an extract of Hypericum perforatum, containing 39% of hyperforin, together. The pharmaceutical composition leads to a potentiation of the anti-inflammatory and anti-microbial effects of the extracts and to stabilization of the hyperforin. The combination is suitable for the external and internal treatment of various skin diseases, in particular skin inflammations and skin ageing, and for the treatment of skin infections with pityrosporon yeast fungi, acne and rosacea.

Abstract: The present invention provides herbal formulas, and compositions thereof, that can treat or reduce the severity, intensity, or duration of asthma and asthma-related symptoms. The compositions may optionally include one or more adjuvants, cytokines, encapsulating materials, or pharmaceutically acceptable carriers or excipients, and may be administered prior to, during, or after the development of asthmatic symptoms in a patient in need thereof.

Abstract: An anti-AIDS agent which comprises, as the active ingredients, one or more components selected from the group consisting of Melastoma villosum Lodd., Dipterocarpus obtusifolius Teijsm ex Miq., Lyophyllum aggregatum, Dictyophora indusiata, pu-erh tea, mentha and stevia. Since the foods having been confirmed as safe in practice are employed, this agent is completely safe to take over a long time.

Abstract: Animal feedstuff having beneficial properties is obtained by adding to a substrate one or more fungal species of the kind that excretes substances into said substrate during its growth which are beneficial to the health, growth or weight gain of an animal, or animals to which the feedstuff is intended and allowing the fungus to grow and/or ferment on the substrate. Suitable substrates are cereal grains, residue of cereal grains, agricultural primary products, agricultural waste products, and other cellulosic materials or a combination of one or more of the same. Suitable fungus species include Cordyceps species, Ganoderma species, Grifola species, Trametes Species, Lentinula species, Antrodia species, Agaricus species, Tremella species, Pleurotus species, Lentinus species, Polypore species, Agaricales species, Ascomycetes species and Basidiomycetes species.

Abstract: A substantially microbe-free composition containing plant growth regulators is produced by culturing a fungal spawn on high carbohydrate medium under suitable conditions. The culture filtrate is sterilized, formulated, and used to enhance plant growth.

Abstract: Inactivated microorganisms are described which comprise agents that are pharmacologically active for human or animal organisms. A process for the preparation of said organisms is further described and their use as medicaments, food integrators or nutritional substances in general, for both human and animal alimentation.

Abstract: Disclosed are extracts of Nigrospora sphaerica as cosmetic skin benefit agents, preferably as skin lightening agents alone or in combination with other skin benefit agents and together with a cosmetic vehicle. The inventive extracts, compositions and methods have effective skin lightening properties, may be easier to deliver to the skin, and are commercially available or cost-effective and available in nature.

Abstract: Disclosed herein is a method for high-yield production of Schizophyllum commune-derived beta-glucan having a homogeneous composition, comprising subjecting mycelia of Schizophyllum commune to liquid culture with an addition of a synthetic adsorbent, and a composition for external application comprising the beta-glucan produced therefrom, which is capable of relieving dry skin conditions, atopic diseases and itching.

Abstract: Phytoceutical composition for the prevention and treatment of hepatic disorders. A specific combination of extracts of plants is taught, as well as the principles for the formulations based on categorizing plants into one of three groups, Energy, Bio-Intelligence and Organization. Such combination has synergistic effects, with minimal side effects.

Abstract: Particular nutritional supplements and protocols emphasize the use of ethylenediamine tetraacetic acid as a mouth rinse, and as an enteric-coated oral pharmaceutical, further supplemented on a daily basis with both a combination of phosphatidyl lipids and alpha lipoic acid and a nutritional supplement containing approximately equal amounts of Reishi and Shiitake mushrooms.

Abstract: A Phytoceutical composition for the prevention and treatment of Multiple Sclerosis (MS) and symptoms is provided. A specific combination of extracts of plants and nutraceuticals is taught, as well as principles for varying the formulations based on categorizing plants into one of three groups, Energy, Bio-Intelligence, and Organization and selecting several plants from each group. Such combinations have synergistic effects, with minimal side effects.

Abstract: A composition that effectively prevents the manifestation of osteoporosis, the formation of osteoclasts and suppresses a decrease of spongy bone density. The composition primarily contains Cordyceps sinensis or its processed product.